PITNEY, HARDIN, KIPP & SZUCH, LLP

711 THIRD AVENUE, 20TH FLOOR
NEW YORK, NEW YORK 10017
PHONE : 212-687-6000
FACSIMILE : 212-682-3485

x Please use the attached page rather than the one previously sent (typographical error in Figure 1)

FACSIMILE COVER PAGE

TO: YOUNG J. KIM

COMPANY: USPTO, Group Art Unit 1612

FACSIMILE NUMBER : 703-308-0294

DATE : January 11, 2001

FROM : Ronald R. Santucci

NO. OF PAGES : 2

Re: USSN 09/381,387 Our Docket No.: 2727-95

COMMENTS As requested accompanied herewith is a Brief Description of the Drawings for the above application. It can probably be inserted on page 3, after line 5, of the English translation unless you feel there is a more suitable place.

Regards,
Ronald Santucci

IF YOU HAVE ANY QUESTIONS REGARDIN THIS TRANSMISSION. PLEASE CALL (212)687-6000

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph of a FACS analysis showing the difference in fluorescence between two populations of agarose beads containing phosphorylated and non-phosphorylated sequences.

Fig. 2 is a graph of a FACS analysis showing the difference in fluorescence between two populations of agarose beads which were mixed and then treated with proteinkinase (PKA) and phosphorylated.

Fig. 3 is a FACS population distribution graph showing the two populations of beads, R2 and R3, which were sorted out by the FACS for further analysis.

Fig. 4 is a tabulation of the pool sequence analysis of the two group of beads, R2 and R3 which were sorted out of the population, as shown in Fig. 3.

Fig. 5 is a graph of the fluorescence of ovalbumin which was labeled with fluorescein/IDA/iron complex according to the invention and then separated by capillary electrophoresis.

Fig. 6 is a graph of the fluorescence of the control protein, glucose oxidase, which was similarly labeled as the ovalbumin in Fig. 5, and then separated by capillary electrophoresis.

Fig. 7 is a graph of a FACS analysis showing the difference in fluorescence between two populations of beads carrying an octapeptide, one population having a serine phosphate and the other an unmodified serine, following treatment with IDA and fluorescein as per the invention.

****
*** RX REPORT ***
****

RECEPTION OK

TX/RX NO	5016
CONNECTION TEL	2126823485
SUBADDRESS	
CONNECTION ID	
ST. TIME	01/11 13:47
USAGE T	00'49
PGS.	2
RESULT	OK